Ambu Valuation

Is AMBU B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AMBU B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AMBU B (DKK113.95) is trading below our estimate of fair value (DKK123.27)

Significantly Below Fair Value: AMBU B is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AMBU B?

Key metric: As AMBU B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AMBU B. This is calculated by dividing AMBU B's market cap by their current earnings.
What is AMBU B's PE Ratio?
PE Ratio	129.2x
Earnings	DKK 235.00m
Market Cap	DKK 30.36b

AMBU B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.6x
Enterprise Value/EBITDA	37.7x
PEG Ratio	4.6x

Price to Earnings Ratio vs Peers

How does AMBU B's PE Ratio compare to its peers?

The above table shows the PE ratio for AMBU B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	30.2x
DEMANT Demant	22.9x	12.4%	DKK 58.0b
EMBLA Embla Medical hf	31x	16.9%	DKK 15.3b
COLO B Coloplast	39.7x	12.9%	DKK 200.7b
GETI B Getinge	27.1x	20.8%	SEK 45.8b
AMBU B Ambu	129.2x	28.1%	DKK 30.4b

Price-To-Earnings vs Peers: AMBU B is expensive based on its Price-To-Earnings Ratio (129.2x) compared to the peer average (30.2x).

Price to Earnings Ratio vs Industry

How does AMBU B's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 Companies	Price / Earnings	Estimated Growth	Market Cap

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: AMBU B is expensive based on its Price-To-Earnings Ratio (129.2x) compared to the European Medical Equipment industry average (29.5x).

Price to Earnings Ratio vs Fair Ratio

What is AMBU B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AMBU B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	129.2x
Fair PE Ratio	43.5x

Price-To-Earnings vs Fair Ratio: AMBU B is expensive based on its Price-To-Earnings Ratio (129.2x) compared to the estimated Fair Price-To-Earnings Ratio (43.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AMBU B forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	DKK 113.95	DKK 126.83 +11.3%	20.1%	DKK 160.00	DKK 76.00	n/a	6
Nov ’25	DKK 129.70	DKK 128.67 -0.8%	18.5%	DKK 145.00	DKK 76.00	n/a	6
Oct ’25	DKK 130.00	DKK 125.50 -3.5%	19.1%	DKK 145.00	DKK 76.00	n/a	6
Sep ’25	DKK 127.95	DKK 126.40 -1.2%	21.9%	DKK 160.00	DKK 76.00	n/a	5
Aug ’25	DKK 140.60	DKK 117.00 -16.8%	25.0%	DKK 138.00	DKK 59.00	n/a	5
Jul ’25	DKK 136.55	DKK 117.00 -14.3%	25.0%	DKK 138.00	DKK 59.00	n/a	5
Jun ’25	DKK 131.40	DKK 111.20 -15.4%	24.9%	DKK 138.00	DKK 59.00	n/a	5
May ’25	DKK 111.95	DKK 107.20 -4.2%	26.4%	DKK 130.00	DKK 52.00	n/a	5
Apr ’25	DKK 113.55	DKK 107.20 -5.6%	26.4%	DKK 130.00	DKK 52.00	n/a	5
Mar ’25	DKK 121.45	DKK 107.20 -11.7%	26.4%	DKK 130.00	DKK 52.00	n/a	5
Feb ’25	DKK 111.60	DKK 105.00 -5.9%	26.7%	DKK 130.00	DKK 52.00	n/a	5
Jan ’25	DKK 105.20	DKK 85.67 -18.6%	26.2%	DKK 115.00	DKK 47.00	n/a	6
Dec ’24	DKK 91.94	DKK 85.67 -6.8%	26.2%	DKK 115.00	DKK 47.00	n/a	6
Nov ’24	DKK 69.86	DKK 89.40 +28.0%	28.2%	DKK 120.00	DKK 53.00	DKK 129.70	5
Oct ’24	DKK 73.86	DKK 95.60 +29.4%	25.6%	DKK 120.00	DKK 53.00	DKK 130.00	5
Sep ’24	DKK 83.56	DKK 96.00 +14.9%	25.3%	DKK 120.00	DKK 53.00	DKK 127.95	5
Aug ’24	DKK 99.16	DKK 101.80 +2.7%	27.0%	DKK 135.00	DKK 59.00	DKK 140.60	5
Jul ’24	DKK 111.65	DKK 102.60 -8.1%	26.9%	DKK 135.00	DKK 59.00	DKK 136.55	5
Jun ’24	DKK 107.50	DKK 102.60 -4.6%	26.9%	DKK 135.00	DKK 59.00	DKK 131.40	5
May ’24	DKK 105.50	DKK 101.60 -3.7%	28.4%	DKK 135.00	DKK 55.00	DKK 111.95	5
Apr ’24	DKK 102.75	DKK 96.25 -6.3%	30.8%	DKK 135.00	DKK 55.00	DKK 113.55	4
Mar ’24	DKK 101.35	DKK 104.60 +3.2%	30.2%	DKK 140.00	DKK 55.00	DKK 121.45	5
Feb ’24	DKK 99.14	DKK 87.80 -11.4%	20.6%	DKK 110.00	DKK 65.00	DKK 111.60	5
Jan ’24	DKK 89.00	DKK 83.40 -6.3%	19.5%	DKK 110.00	DKK 65.00	DKK 105.20	5
Dec ’23	DKK 91.70	DKK 83.20 -9.3%	19.8%	DKK 110.00	DKK 64.00	DKK 91.94	5
Nov ’23	DKK 88.88	DKK 76.50 -13.9%	11.7%	DKK 85.00	DKK 64.00	DKK 69.86	4

Analyst Forecast: Target price is less than 20% higher than the current share price.